(Q30238961)

12 June 2017

title

Virus-induced hepatocellular carcinoma with special emphasis on HBV. (English)

1 reference

12 June 2017

main subject

hepatocellular carcinoma

1 reference

Ming Wang

1

1 reference

12 June 2017

Dong Xi

series ordinal

2

1 reference

12 June 2017

Qin Ning

series ordinal

3

1 reference

12 June 2017

publication date

17 January 2017

1 reference

12 June 2017

published in

Hepatology international

1 reference

12 June 2017

volume

11

1 reference

12 June 2017

issue

2

1 reference

12 June 2017

page(s)

171-180

1 reference

Natural history of chronic hepatitis B: phases in a complex relationship

12 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Global cancer statistics, 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

The changing pattern of epidemiology in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

The global impact of vaccination against hepatitis B: a historical overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

The global health burden of infection-associated cancers in the year 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Inflammation and cancer: an ancient link with novel potentials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Roles of tumor suppressors in regulating tumor-associated inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

STK4 regulates TLR pathways and protects against chronic inflammation-related hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Factors predicting occurrence and prognosis of hepatitis-B-virus-related hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti-tumour immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

The functional impairment of HCC-infiltrating γδ T cells, partially mediated by regulatory T cells in a TGFβ- and IL-10-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Downregulation of FGL2/prothrombinase delays HCCLM6 xenograft tumour growth and decreases tumour angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Hepatitis B virus-induced hFGL2 transcription is dependent on c-Ets-2 and MAPK signal pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Fibrinogen-like protein 2/fibroleukin prothrombinase contributes to tumor hypercoagulability via IL-2 and IFN-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Adenovirus-mediated artificial microRNA against human fibrinogen like protein 2 inhibits hepatocellular carcinoma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Recurrent targeted genes of hepatitis B virus in the liver cancer genomes identified by a next-generation sequencing-based approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Hepatitis B virus, HBx mutants and their role in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Hepatitis B virus HBx protein interactions with the ubiquitin proteasome system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Hepatitis B virus X (HBx) play an anti-apoptosis role in hepatic progenitor cells by activating Wnt/β-catenin pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Modulation of apoptotic signaling by the hepatitis B virus X protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Hepatitis B virus X protein induces EpCAM expression via active DNA demethylation directed by RelA in complex with EZH2 and TET2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Hepatitis B virus X protein promotes P3 transcript expression of the insulin-like growth factor 2 gene via inducing hypomethylation of P3 promoter in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

RNA helicase DEAD box protein 5 regulates Polycomb repressive complex 2/Hox transcript antisense intergenic RNA function in hepatitis B virus infection and hepatocarcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Hepatitis B virus X protein induces the histone H3 lysine 9 trimethylation on the promoter of p16 gene in hepatocarcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Molecular mechanisms of HBV-associated hepatocarcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Hepatitis B virus and hepatocellular carcinoma at the miRNA level

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Hepatocellular carcinoma and hepatitis B surface protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Mechanisms of HBV-induced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Stop feeding cancer: pro-inflammatory role of visceral adiposity in liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Long-term Effects of Hepatitis B Immunization of Infants in Preventing Liver Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Childhood Cancer Among Alaska Natives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Effectiveness of surveillance for hepatocellular carcinoma in clinical practice: A United States cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Prevention of hepatitis B virus-associated liver diseases by antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Significance of viral status on recurrence of hepatitis B-related hepatocellular carcinoma after curative therapy: A meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

How have the recent advances in antiviral therapy impacted the management of virus-related hepatocellular carcinoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Role of lamivudine with transarterial chemoembolization in the survival of patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Prognosis of hepatocellular carcinoma: the BCLC staging classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Management of hepatocellular carcinoma: An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Personalized therapy for hepatocellular carcinoma: Where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Down-regulation of NTCP expression by cyclin D1 in hepatitis B virus-related hepatocellular carcinoma has clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Update on epidemiology of hepatitis B and C in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Slow decline of hepatitis B burden in general population: Results from a population-based survey and longitudinal follow-up study in Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Molecular Evolution and Phylodynamics of Acute Hepatitis B Virus in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Hepatitis B virus genotypes: epidemiological and clinical relevance in Asia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Seroepidemiology and occult hepatitis B virus infection in young adults in Banjarmasin, Indonesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Hepatitis B virus genotypes: global distribution and clinical importance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Characterization of hepatitis B virus genotypes and quantitative hepatitis B surface antigen titres in North American tertiary referral liver centres

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Therapeutic implications of hepatitis B virus genotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-016-9779-5

Incidence of hepatocellular carcinoma in children in Khon Kaen before and after national hepatitis B vaccine program

21 January 2018

1 reference

12 December 2020

Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region

1 reference

12 December 2020

Adjuvant interferon for early or late recurrence of hepatocellular carcinoma and mortality from hepatocellular carcinoma following curative treatment: A meta-analysis with comparison of different types of hepatitis

1 reference

12 December 2020

Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer

1 reference

12 December 2020

Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients

1 reference

12 December 2020

Randomized controlled trial of screening for hepatocellular carcinoma

1 reference

12 December 2020

HBV preS2 transactivates FOXP3 expression in malignant hepatocytes

1 reference

12 December 2020

10.1007/S12072-016-9779-5

Identifiers

DOI

1 reference

Dimensions Publication ID

12 June 2017

1002039030

0 references

Fatcat ID

release_yt6k4letjjfstgeaykjivb7o3a

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/yt6k4letjjfstgeaykjivb7o3a

24 November 2022

mapped directly with Wikidata item

1 reference